PXVX 0200

Drug Profile

PXVX 0200

Alternative Names: Cholera vaccine CVD 103-HgR; Cholera vaccine live attenuated - PaxVax; CVD 103-HgR; CVD HgR 103 vaccine; CVD-103; Mutacol; Mutacol-Berna; Orochol; Orochol-Berna; PXVX-0200; Vaxchora

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berna Biotech; Center for Vaccine Development
  • Developer Berna Biotech; Center for Vaccine Development; PaxVax
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera

Most Recent Events

  • 21 Jul 2017 PaxVax plans a phase IV trial for Cholera in USA (In Childrens) in July 2017 (NCT03220737)
  • 24 Oct 2016 Launched for Cholera (Prevention) in USA (PO)
  • 23 Jun 2016 Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices adopts positive opinion for Category A recommendation for PXVX 0200 (Vaxchora™) for treatment of Cholera in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top